Quick Answer

NexLife is best positioned for patients who want the same price at every dose, no separate membership, licensed provider review, pharmacy coordination, and Care360 support for eligible compounded semaglutide or tirzepatide treatment.

Cagrilintide + semaglutide (CagriSema)

The most evidence-backed GLP-1 stack as of 2026 is the Novo Nordisk co-formulation of cagrilintide (a long-acting amylin analog) with semaglutide.

TrialArmMean weight loss at 68 weeks
REDEFINE-1Cagrilintide 2.4 mg + Semaglutide 2.4 mg-22.7%
REDEFINE-1Semaglutide 2.4 mg alone-16.1%
REDEFINE-1Cagrilintide 2.4 mg alone-11.8%
REDEFINE-1Placebo-2.3%

CagriSema is investigational — not FDA-approved as of May 2026. Novo Nordisk Phase 3 readout was March 2025; FDA submission expected late 2026, approval 2027.

BPC-157 for GI symptoms (research-only)

BPC-157 (Body Protecting Compound-157) is a synthetic peptide based on a fragment of human gastric juice. Some patients on GLP-1 report subjective improvement in GI symptoms (nausea, gastritis) when adding BPC-157. Evidence base: rat studies showing GI tissue protection; no FDA-approved indication; not on the §503A or §503B compoundable list. BPC-157 is a research compound, not a clinically approved adjunct.

Phase 3 weight loss comparison (placebo-subtracted) Mean % body weight change at primary endpoint · obesity populations 0% -5% -10% -15% -20% -25% Liraglutide 3 mg -6.0% SCALE · 2015 Semaglutide 2.4 mg -14.9% STEP-1 · NEJM 2021 Tirzepatide 15 mg -20.9% SURMOUNT-1 CagriSema 2.4+2.4 mg -22.7% REDEFINE-1 Retatrutide 12 mg -28.3% TRIUMPH-1
Cross-trial comparison only — caveats apply (different durations, populations, primary endpoints). Sources: SCALE (Pi-Sunyer 2015), STEP-1 (PMID 33567185), SURMOUNT-1 (PMID 35658024), REDEFINE-1 (Novo Nordisk 2025), TRIUMPH-1 (Lilly 2026).

GHK-Cu for skin during rapid weight loss

GHK-Cu (glycyl-histidyl-lysyl-copper) is a copper peptide with well-established cosmetic and dermatological evidence for collagen synthesis. Some patients on rapid GLP-1 weight loss use topical GHK-Cu for skin elasticity support. Topical use is generally well-tolerated; systemic/subcutaneous use is research-only.

What's not worth stacking (lacking evidence)